EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The safety assessment of ustekinumab on psoriasis and psoriatic arthritis: A real-world analysis based on the FDA adverse event reporting system database

Yu Zheng, Xiao-Jing Gao, Ji-Jun Huang, Xiang-Ming Chen, Yue Liao, Jia-Min Liu, Yan-Ling Zheng, Yu-Yang Zhao, Rui-Lian Ding, Xiao-Min Li, Jin Bu, Er-Xia Shen

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.114339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Yu Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, Jiangsu 210042, Ch…. Hauptthemen laut MEDLINE: Psoriasis, Ustekinumab, Arthritis, Psoriatic, Dermatologic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To assess safety of ustekinumab (UST) on treatment of patients with psoriasis and psoriatic arthritis (PsA) by analyze UST related adverse drug events (ADEs). METHODS: Data on ADEs associated with UST on psoriasis and PsA were collected from the fourth quarter of 2009 through the third quarter of 2024 in the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FEARS) database. A variety of signal quantization techniques such as reporting odds ratio (ROR), proportional reporting ratio (PRR), bayesian confidence propagation neural network (BCPNN), and multi-item gamma poisson shrinker (MGPS) are used for analysis. RESULTS: A total of 67,765 ADE reports with UST on psoriasis and PsA as the primary suspected agent covered 25 system organ classes (SOCs). The three most common ADEs are infections and infestations (n = 9698), general disorders and administration site conditions (n = 6336), and injury, poisoning, and procedural complications (n = 6091). Specifically, reproductive system diseases (n = 262) was identified as unique adverse reactions not mentioned in official drug labels. At the preferred term (PT) level, the most common ADEs were psoriasis exacerbation (n = 3486), lower respiratory tract infection (n = 1302) and latent tuberculosis (n = 121). Strong yet rare signals, including notalgia paraesthetica (n = 3, empirical bayesian geometric mean [EBGM] 154.7) and chronic actinic dermatitis (n = 3, EBGM 101.15), were also detected. Compared to patients with PsA, patients with psoriasis treated with UST exhibit significantly stronger associations with hepatobiliary disorders (n = 955, ROR 2.44, PRR 2.4, information component [IC] 1.26, EBGM 2.4) and neoplasms (n = 3150, ROR 2.61, PRR 2.49, IC 1.31, EBGM 2.49). Spontaneous reports consistently demonstrated higher signal strength for infections and skin disorders compared to healthcare professional (HCP) reports. In contrast, at the PT level, HCP reports tended to emphasize stronger signals for rare or specific conditions. CONCLUSION: This study highlights a spectrum of UST-associated ADEs covering 25 SOCs in the treatment of patients with psoriasis and PsA, which emphasizes the need for vigilant clinical monitoring, particularly for infections, hepatobiliary disorders, and rare but high-signal events such as notalgia paraesthetica, chronic actinic dermatitis and pure testicular seminoma stage I. Clinicians should combine insights from both spontaneous and HCP reports and pay special attention to infections and reproductive system disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisUstekinumabArthritis, PsoriaticDermatologic AgentsDrug-Related Side Effects and Adverse ReactionsHumansUnited StatesUnited States Food and Drug AdministrationAdverse Drug Reaction Reporting SystemsDatabases, FactualMaleFemaleMiddle AgedBayes TheoremAdult

Stichwörter der Autor:innen

Adverse drug event (ADE)Adverse drug reactionFDA adverse event reporting system database (FAERS)PsoriasisPsoriatic arthritis (PsA)Real-world data analysisUstekinumab (UST)

Substanzen

UstekinumabDermatologic Agents

Autor:innen und Institutionen

  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, Jiangsu 210042, China.
  • Guangzhou Medical University, School of Basic Medical Sciences, Xinzao Town, Panyu District, Guangzhou, Guangdong 511436, China.
  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, Jiangsu 210042, China; Qingdao Municipal Center for Disease Control & Prevention, Qingda…
  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, Jiangsu 210042, China. Electronic address: bujin@pumcderm.cams.cn.
  • Guangzhou Medical University, School of Basic Medical Sciences, Xinzao Town, Panyu District, Guangzhou, Guangdong 511436, China; Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and De…

Zitieren

APA

Zheng, Y., Gao, X. J., Huang, J. J., Chen, X. M., Liao, Y., Liu, J. M., Zheng, Y. L., Zhao, Y. Y., Ding, R. L., Li, X. M., Bu, J., & Shen, E. X. (2025). The safety assessment of ustekinumab on psoriasis and psoriatic arthritis: A real-world analysis based on the FDA adverse event reporting system database. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114339

Vancouver

Zheng Y, Gao XJ, Huang JJ, Chen XM, Liao Y, Liu JM, et al. The safety assessment of ustekinumab on psoriasis and psoriatic arthritis: A real-world analysis based on the FDA adverse event reporting system database. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114339

BibTeX
@article{Zheng2025,
  author = {Zheng, Yu and Gao, Xiao-Jing and Huang, Ji-Jun and Chen, Xiang-Ming and Liao, Yue and Liu, Jia-Min and Zheng, Yan-Ling and Zhao, Yu-Yang and Ding, Rui-Lian and Li, Xiao-Min and Bu, Jin and Shen, Er-Xia},
  title = {The safety assessment of ustekinumab on psoriasis and psoriatic arthritis: A real-world analysis based on the FDA adverse event reporting system database},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.114339}
}
Kostenlos starten →